HIV

Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
torsdag, maj 9, 2024
PFS, FDA, SLATE, Administration, Research, HLA, Death, CRC, Doctor of Philosophy, National Cancer Institute, Vaccine, Development, IND, Melinda French Gates, NCI, AACR, Food, ESCMID, Roche, Messenger, HIV, Therapy, CEPI, Neoplasm, Infection, Gritstone bio, DNA, GMP, Clinical trial, Progression-free survival, Human services, Immunotherapy, Spark Therapeutics, MD, Disease, Patient, Acquisition, VAF, PD, COVID-19, Pharmaceutical industry

-- Gritstone to host conference call today at 4:30pm ET --

Key Points: 
  • In April 2024, Gritstone appointed Stephen Webster to its Board of Directors.
  • Mr. Webster was the Chief Financial Officer of Spark Therapeutics from July 2014 until its acquisition by Roche for $4.3 billion in December 2019.
  • Gritstone expects to share mature PFS data and additional long-term ctDNA data in the third quarter of 2024.
  • In April 2024, Gritstone presented a poster highlighting the durability and potential broad utility of its samRNA COVID-19 vaccine at ESCMID Global 2024.

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Retrieved on: 
torsdag, maj 9, 2024
HIV/AIDS, Nephrology, FDA, Parkinson's disease, New chemical entity, CTD, Woman, Pulmonary hypertension, Blood, Food, Imatinib, NME, Connective tissue disease, PAH, Partnership, IND, Cardiology, Disease, Therapy, Patent, Ventricular septal defect, HIV, Clinical trial, HERG, Division, Investigational New Drug, Pharmaceutical industry

BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001Pro (“Pro”) as a candidate treatment for Pulmonary Arterial Hypertension (PAH). Following review of the final meeting minutes, Inhibikase is preparing the Investigational New Drug (IND) application.

Key Points: 
  • Following review of the final meeting minutes, Inhibikase is preparing the Investigational New Drug (IND) application.
  • If approved, IkT-001Pro could be a branded product with all the value drivers of a novel treatment for an indication of high unmet medical need.
  • In parallel, the Company has initiated discussions with potential strategic partners in order to advance the development of Pro for Pulmonary Arterial Hypertension.
  • Pulmonary Arterial Hypertension is a rare disease of the pulmonary microvasculature.

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
torsdag, maj 9, 2024
FDA, Probability, Gilead Sciences, Food, Pembrolizumab, OPSCC, Partnership, IND, Roche, ASCO, Arenavirus, PRIME, Patient, EMA, Lung, Hepatitis B, HIV, Clinical trial, Annual general meeting, Food and Drug Administration, HBV, Pharmaceutical industry

The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.

Key Points: 
  • The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.
  • Effective April 25, 2024, HOOKIPA regained full control of the associated intellectual property portfolio and has full collaboration and licensing rights for this program.
  • HOOKIPA received FDA clearance of its IND application in the fourth quarter of 2023 and expects to initiate a Phase 1 clinical trial of HB-500 in people with HIV in the second quarter of 2024.
  • On January 29, 2024, HOOKIPA provided an update on its business priorities and oncology partnership programs.

Immunocore reports first quarter financial results and provides a business update

Retrieved on: 
onsdag, maj 8, 2024
CTA, Total, Research, HLA, IND, ASCO, Research and development, BMY, Annual report, Drug, Autoimmune disease, APC, HIV, Bristol Myers Squibb, TCR, Autoimmunity, Infection, PRAME, Treatment, EMA, GMP, Clinical trial, Investigational New Drug, Platinum, ImmTAC, Nivolumab, Security (finance), Form 10-Q, Half-life, Patient, Immune system, Pharmaceutical industry

& ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Net loss for the first quarter of 2024 was $24.4 million compared to a net loss of $19.4 million in the same period in 2023.
  • The first quarter basic and diluted loss per share was $0.49, compared to $0.40 for the first quarter of 2023.
  • This includes net cash proceeds of $390.2 million from the Company’s offering of convertible notes in February 2024.

National Implementation of Supportive Housing Initiative to Close the Gap on HIV-Related Inequities Outlined in the National HIV/AIDS Strategy

Retrieved on: 
tisdag, maj 7, 2024
University, JSI, GMHC, SPNS, HIV/AIDS Bureau, Corporation, Social isolation, Woman, SURE, Housing, Development aid, Arrest, Partnership, Violence, White, ART, Mental health, Community, MPH, University of Massachusetts Lowell, Homelessness, HIV, CSH, Queer, HRSA, Implementation, Organization, Imprisonment, Service, Nursing

The project will address the intersectionality among housing status, identification with one of the three priority populations, and HIV-related health outcomes.

Key Points: 
  • The project will address the intersectionality among housing status, identification with one of the three priority populations, and HIV-related health outcomes.
  • The project is funded through HRSA’s Ryan White HIV/AIDS Program Part F Special Projects of National Significance (SPNS) Program.
  • "This innovative initiative represents opportunities to integrate HIV care and behavioral health with housing interventions to improve health outcomes among priority populations of people with HIV."
  • Housing is a social determinant of health that has a substantial impact on HIV prevention and care outcomes .

Bloodshot Billboards: Eye Syphilis is Serious

Retrieved on: 
tisdag, maj 7, 2024
AIDS, Health, General Health, Healthcare Reform, Public Policy, Pharmaceutical, Other Policy Issues, Public Safety, Infectious Diseases, Hospitals, Government, Syphilis, Woman, MSM, CDC, Paratriathlon, URL, PLWH, CNN, STI, Patient, AIDS Healthcare Foundation, Floater, Multimedia, HIV, AHF, Pharmaceutical industry

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    Cases of syphilis are on the rise nationwide, and according to CNN , researchers in Chicago found more than two dozen cases last year of patients reporting unusual symptoms, such as vision and eye problems consistent with ocular syphilis.
  • “Syphilis itself is at an all-time high, and cases of ocular syphilis are likely to be underreported,” said Dr. Michael Dube, National Medical Director for AHF’s Public Health Division.
  • All five women had ocular syphilis from sexual contact with the same man who had asymptomatic syphilis.
  • If a client diagnosed with syphilis has any new issues with their eyes, they should be screened for ocular syphilis.

Global Health Leaders Unite to Confront Urgent Public Health Crisis of Antimicrobial Resistance

Retrieved on: 
tisdag, maj 7, 2024
Public Policy, Government, Other Communications, General Health, Health, Other Policy Issues, Infectious Diseases, Communications, Public, Cancer, Antimicrobial resistance, Social isolation, Pathogenic bacteria, Risk, Malaria, CDC, Animal, AMR, Death, Biotechnology Innovation Organization, Parent, Research, BIO, Plant, Friends, Environment, Human, Partnership, Disease, Family, JD, Patient, Caregiver, Face, Diary, Child, HIV, Infection, Associate, TB, COVID-19, Diplomatic rank, Pharmaceutical industry

Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.

Key Points: 
  • Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.
  • "Antimicrobial resistance is an urgent global public health threat that poses risks to modern medicine, the health of humans, animals, plants, the environment, and the global economy.
  • These stories are poised to transform the AMR crisis from a distant concept to a relatable and urgent reality.
  • Putting a human face on this global emergency is critical to motivating action that can change the course of this escalating health crisis.

PLK Targeted Therapies Market & Clinical Trials 2024: Onvansertib Leading the Way in PLK1 Inhibition, Pioneering Breakthroughs in Small Cell Lung Cancer and Chronic Myelomonocytic Leukemia Treatment - ResearchAndMarkets.com

Retrieved on: 
tisdag, maj 7, 2024
Health, Clinical Trials, Cytokinesis, Immunotherapy, Cancer, Chronic myelomonocytic leukemia, Inflammation, Disorder, Safety, Breast cancer, Viral, Apoptosis, SCLC, Cell proliferation, Research, Cell cycle, Carcinoma, DNA, Mitosis, Indication, Patient, Rheumatoid arthritis, Hepatitis B virus, Virus, Proteolysis targeting chimera, Multiple sclerosis, HIV, Messenger, PLK, Lupus, Genome, Biomarker, Medicine, PLK1, DA, HBV, Pharmaceutical industry

The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Onvansertib, a PLK1 inhibitor developed by Cardiff Oncology, is currently the most advanced candidate in clinical trials.
  • The progression of these candidates through the pipeline reflects the growing interest and confidence in PLK targeted therapies.
  • In conclusion, PLK targeted therapies are a rapidly developing field with revolutionary promise across a wide range of disease areas.

U.S. Medical Kiosks Market Insights Report 2024-2029, with Data on 39 Key Vendors Including Fabcon, Meridian, Verifone, Xiphias Software Technologies and Redyref - ResearchAndMarkets.com

Retrieved on: 
måndag, maj 6, 2024
Health, Health Technology, Online, USD, Cancer, Pharmacy, Virtual reality, EHR, Communication, Artificial intelligence, Prescription, Convenience, Digital, Health information management, Patient, Mental health, HIV, Chronic kidney disease, Pharmacist

The U.S. medical kiosk market report contains exclusive data on 39 vendors.

Key Points: 
  • The U.S. medical kiosk market report contains exclusive data on 39 vendors.
  • The leading medical kiosk market vendors are Fabcon, Meridian, Verifone, Xiphias Software Technologies, and Redyref.
  • The rapidly changing technological environment can adversely affect vendors as customers expect continual innovations and upgrades in the medical kiosk market.
  • By product type, the self-service kiosk segment has the largest share of over 37% in the U.S. medical kiosk market.

NANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIV

Retrieved on: 
onsdag, maj 8, 2024
Nuclear power plant, Doctor of Philosophy, Research, Success, Nanoparticle, Therapy, Bill, Melinda French Gates, HIV, Pharmaceutical industry

BOSTON, May 8, 2024 /PRNewswire/ -- Nanite, Inc. today announced a $1.8M grant from the Bill & Melinda Gates Foundation to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics.

Key Points: 
  • Nanite's proprietary SAYERTM platform combines AI-driven polymer design with multiplexed in vivo screening to develop best-in-class polymer nanoparticles [PNPs] for tissue-specific delivery.
  • Success would represent a significant breakthrough in HIV management, particularly in populations with limited access to medical care.
  • "One of our long-stated goals is to develop technologies that allow the benefits of gene therapy to be accessible to a wider patient population, particularly in underserved communities.
  • Nanite is dedicated to accelerating the impact of genetic medicine for the treatment of HIV."